Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 132 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo for methotrexate Clear all
Terminated Phase 2 Interventional Results available

CD40L Antagonism in Rheumatoid Arthritis (RA)

NCT05306353
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

NCT01900431
View directory record Official record
Conditions
Uveitis
Interventions
Sarilumab, Prednisone, Methotrexate, Folic/folinic acid, Placebo (for Sarilumab)
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Worcester, Massachusetts • Omaha, Nebraska • Slingerlands, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 4 Interventional Results available

Myositis Interstitial Lung Disease Nintedanib Trial

NCT05799755
View directory record Official record
Conditions
Myositis Associated Interstitial Lund Disease (MA-ILD)
Interventions
Nintedanib, Placebo, Standard of Care
Drug
Lead sponsor
Rohit Aggarwal, MD
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis

NCT03233230
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
M2591 25 mg QD, M2951 75 mg QD, M2951 50 mg BID, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Phoenix, Arizona • San Leandro, California • DeBary, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)

NCT00520572
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AZD9056, Etanercept, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Aventura, Florida • Orlando, Florida • Sarasota, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 4 Interventional Results available

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout

NCT03994731
View directory record Official record
Conditions
Gout
Interventions
Pegloticase, methotrexate, placebo, folic acid, gout flare prophylaxis regimen, fexofenadine, acetaminophen, methylprednisolone
Biological · Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
60
States / cities
Birmingham, Alabama • Anchorage, Alaska • Flagstaff, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of 2 Oral Doses of PG-760564 in Rheumatoid Arthritis (RA) Patients Receiving Methotrexate

NCT00369928
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PG-760564, Placebo dose
Drug
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years to 70 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
24
States / cities
Hot Springs, Arkansas • Beverly Hills, California • Mission Viejo, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2011 · Synced Oct 17, 2026, 5:28 AM EDT
Terminated Phase 3 Interventional Results available

A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate

NCT01198002
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LY2127399, Placebo Q2W, Placebo Q4W, Methotrexate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,041 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
75
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 17, 2026, 5:28 AM EDT
Terminated Phase 2 Interventional

BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis

NCT00458861
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BG9924, Placebo Comparator
Biological · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

Inflammation and Coronary Endothelial Function

NCT02366091
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Methotrexate, Colchicine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 17, 2026, 5:28 AM EDT
Completed No phase listed Observational Results available

PET/CT Imaging Companion Study To ACTG A5314

NCT02312219
View directory record Official record
Conditions
HIV, Inflammation, Atherosclerosis
Interventions
Folic Acid, Placebo, Low Dose Methotrexate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate

NCT00847613
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
37
States / cities
Huntsville, Alabama • Tucson, Arizona • San Diego, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 17, 2026, 5:28 AM EDT
Terminated Phase 2 Interventional Results available

Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers

NCT01217814
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, Placebo, Golimumab, methotrexate (MTX), Folic/folinic acid
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Freehold, New Jersey • New York, New York • Jackson, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 17, 2026, 5:28 AM EDT
Terminated Phase 2 Interventional

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

NCT01679951
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, JNJ-38518168 (3 mg), JNJ-38518168 (10 mg), JNJ-38518168 (30 mg), Methotrexate
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

NCT02889796
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, Adalimumab, Placebo to match adalimumab, MTX
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
48
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 17, 2026, 5:28 AM EDT
Terminated Phase 2 Interventional

A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT01862224
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
JNJ-38518168, Placebo, Methotrexate
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy

NCT00689728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
LY2127399, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
Birmingham, Alabama • Mesa, Arizona • Palm Desert, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT00361335
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Golimumab, Methotrexate, Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
20
States / cities
Peoria, Arizona • Aventura, Florida • Orlando, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

NCT02760407
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w, Placebo q2w
Drug
Lead sponsor
R-Pharm International, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
64
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)

NCT02663622
View directory record Official record
Conditions
Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia
Interventions
Efprezimod alfa, Methotrexate, Tacrolimus, Placebo
Drug
Lead sponsor
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Indianapolis, Indiana • Ann Arbor, Michigan • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 17, 2026, 5:28 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis

NCT02531633
View directory record Official record
Conditions
Giant Cell Arteritis
Interventions
Sirukumab, Placebo to match sirukumab, Prednisone, Placebo to match prednisone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
13
States / cities
Aurora, Colorado • Boca Raton, Florida • Naples, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis

NCT06073093
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SAR441566, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
17
States / cities
Northridge, California • Upland, California • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 4 Interventional Results available

Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis

NCT02831855
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, Methotrexate, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
59
States / cities
Huntsville, Alabama • Gilbert, Arizona • Peoria, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Oct 17, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350

NCT02983227
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GDC-0853
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 76 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Glendale, Arizona • Covina, California • El Cajon, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 17, 2026, 5:28 AM EDT